U.S. Department of Health and Human Services

Diabetes, Endocrine, and Metabolic Disease Translational Research

The Diabetes, Endocrine, and Metabolic Disease Translational Research program promotes studies to advance basic science towards practical applications leading to improvements in the diagnosis and treatment of diseases of interest to the Division of Diabetes, Endocrinology, & Metabolic Diseases at the NIDDK such as obesity, type 1 and type 2 diabetes and related aspects of endocrinology and metabolism, other metabolic disorders, and specific aspects of cystic fibrosis.  The program encourages efforts to develop the sound evidence base needed to advance proteomic, metabolomic, genomic, epigenomic, and other ‘omic findings towards applications to clinical studies, such as for precision medicine. Additionally, this program encompasses the development of the necessary supporting technologies to accomplish those goals. Studies that fall within this program may include: the identification of genes and epigenetic factors that influence variable pharmacodynamic and pharmacokinetic responses to therapeutic agents; systems biology approaches to determine how higher-level properties of complex biological systems arise from the interactions among their parts; interdisciplinary therapeutics discovery research to advance the validation of targets (see the therapeutics discovery pipeline here); and the identification of pre-therapeutic candidates through the development and implementation of drug discovery assays. Of particular interest to this program are models that are capable of predicting disease risk or therapeutic efficacy. ​​​​​​​​​​​​​​​​​​​​

 NIDDK Staff

Aaron Pawlyk, Ph.D.​Key regulators of intermediary metabolism; drug discovery; pharmacogenetics and precision medicine.
Salvatore Sechi, Ph.D.Proteomics, Systems Biology, and Structural Biology as applied to diabetes, metabolic, and endocrine diseases


 Related Funding Opportunities

Posted DateTitleFull Announcement
2/1/2017Development of Highly Innovative Tools and Technology for Analysis of Single Cells (STTR) (R41/R42) (Summary) PA-17-148
2/1/2017Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44) (Summary) PA-17-147
1/24/2017Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R43/R44) (Summary) PA-17-130
1/24/2017Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R41/R42) (Summary) PA-17-131
1/17/2017Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01) (Summary) PAR-17-123
View More Funding Opportunities

The resources listed below include reagents, data, protocols, etc. If you would like to utilize any of these resources, contact the person associated with the resource.


 Research Resources

Resource NameDescription
Mouse Metabolic Phenotyping Centers

The MMPC is a National Institutes of Health-sponsored resource that provides experimental testing services to scientists studying diabetes, obesity, diabetic complications, and other metabolic diseases in mice.

Integrated Islet Distribution Program

The goal of the Integrated Islet Distribution Program (IIDP) is to work with the leading islet isolation centers in the U.S. to distribute high quality human islets to the diabetes research community, in order to advance scientific discoveries and…

Action to Control Cardiovascular Disease Risk in Diabetes Follow-up Study
ACCORDION (sponsored by NHLBI) is a prospective, observational follow-up study of at least 8000 participants who were treated and followed in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.  Treatment in ACCORD ended in 2009 and…
Action for Health in Diabetes
Look AHEAD is a 16-center, randomized clinical trial investigating the long-term health effects of an intensive lifestyle intervention designed to produce weight loss. Look AHEAD enrolled 5,145 overweight or obese participants with type 2 diabetes…
Diabetic Complications Consortium
The goal of the NIDDK-sponsored Diabetic Complications Consortium (DiaComp) is to foster communication and collaboration between investigator communities involved in complications research.  Toward this goal, DiaComp: (1) sponsors annual meetings in…

View Additional Research Resources


 NIDDK Active Trials in Diabetes and Endocrine Disease

​View related clinical trials from ClinicalTrials.gov​.


 Related Study Sections

​Study sections conduct initial peer review of applications in a designated scientific area. View related study sections ​ from the NIH's Center for Scientific Review.​